Midatech Pharma : AGM Presentation 2019

Midatech Pharma AGM Update

June 2019

Using our forefront platform technologies 'make medicines better'

Technologies That 'Make Medicines Better '

Focus on rare cancer or tumour diseases of neurological nature

• Technologies aimed at improving bio-deliveryand bio-distributionof existing agents

Each technology is delivering:

1. Successful clinical translation to date

1. Ongoing clinical programmes

1. Multiple opportunities beyond current programmes

Q-Sphera ™MidaSolve™MidaCore ™

• Sustained delivery	• Local delivery	• Targeted delivery
• Precision clinical performance	• Converts oral meds into liquid meds	• Ultra-small size
• Advanced technology manufacturing	• Increases routes of administration	• Can bind multiple agents (targeting
• Clear competitive advantage	injected direct to tumour	and therapeutic)

Technologies focussed on improving biodelivery and biodistribution of existing medications

Lead programme:	Lead programme:	Early research
MTD201	MTX110

2

2018 Highlights

Compelling Product Candidates

Novel delivery platforms addressing carcinoid cancer & acromegaly and paediatric brain cancer

Refocused Strategy

Following divestment of commercial businesses, R&D and clinical programs are primary focus

Solid Clinical Progress

Key clinical programs into clinic - MTD201 strong data, MTX110 solid progress; technologies validated

Strong Partnerships

Out-license of programs & platforms to CMS for Greater China/SE Asia, a strong vote of confidence in MTP

Robust IP Portfolio

36 patent families with 107 issued patents covering core technology platforms

Secure Cash Runway

Successful $16.9M fundraise covers clinical goals through mid-2020, plus $9.5m Spanish finance for manufacturing scale up

(1)	Converted to USD based on 06/02/2019 conversion rate of $1.26 per £	3

Q -Sphera MTD201 For Neuroendocrine Tumours & Acromegaly

	$2bn market	Octreotide	Midatech's
	MTD201
	dominated by	mainstay of
	being
	Sandostatin®	medical
	developed as
	LAR® and	treatment
Market	alternative to
Somatuline	for both
	Sandostatin®
	Autogel for	carcinoid
	LAR® and
	past ≈20	and
	Somatuline
	years	acromegaly
	Autogel

Based on advanced Q-Sphera™ technology to

'Make Medicines Better'

Formulation	Manufacturing	Proven clinical
technology	Patents
technology	benefits +/-
giving full	beyond
giving faster,	longer dosing	Competitive
control over	2030
simpler, less	interval +/-
particle size	converts	Advantage
toxic, higher	higher doses +/-
and release	into Iong
yield processes,	subcutaneous
kinetics,	term IP
converts into	administration
converts into	and know
sustainable	convert into
demonstrable	how
and efficient	clear competitive
clinical	protection
manufacturing	advantage
benefits

4

MTD201 Compelling Phase I Data vs Sandostatin LAR (SLAR)

Pharmacodynamics Normalisation of Growth Hormone

Pharmacokinetics Favourable Release Kinetics and Less Variability

Needle Size Smaller and Less Painful

• Small 21G needle for MTD201, whereas SLAR uses 19G needle - 40% smaller surface area
• Lower injection pain (8% vs. 25%) and lower injection site tenderness (8% vs 83%) (MTD201- 101)

Reconstitution Time Quicker; and Stability Longer

• MTD201 Reconstitution from opening pack to injection in under 10 minutes, stable for 2 hrs
• SLAR reconstitution around 40 minutes by the

published method, must be used immediately	5